C-REACTIVE PROTEIN (CRP) PLUS NASOPHARYNGEAL/OROPHARYNGEAL AND WHOLE BLOOD PNEUMOCOCCAL PCR DENSITY TO DIFFERENTIATE PNEUMOCOCCAL FROM NON-PNEUMOCOCCAL PNEUMONIA IN CHILDREN IN THE 7-COUNTRY PNEUMONIA ETIOLOGY RESEARCH FOR CHILD HEALTH (PERCH) CASE-CONTROL STUDY

Melissa M. Higdon for the PERCH Study Group

ent of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Department of Pathology, University of Otago, Christchurch; Microbiology Unit, Canterbury Health Laboratories, Christchurch, New Zealand; Kenya Medical Research Institute Wellcome Trust Research Programme, Kilifi, Kenya liatrics and Medicine, Center for Vaccine Development, University of Maryland School of Medicine, Balti nore, Maryland; Centre pour le Développement des Vaccins (CVD Mali), Bamako, Mali; Boston University School of Public Health, Boston, I Aedical Research Council: Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology/National Research Foundation: Vaccine Preventable Disease Unit; Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia; Global Disease Detec ment of Clinical Medicine University of Oxford United Kingdo

INTRODUCTION

High pneumococcal PCR density in the naso/oropharynx (NP/OP) and whole blood (WB) is associated with pneumococcal pneumonia [1], but their imperfect specificity limits its use in ascribing etiology. Elevated C-reactive protein (CRP) is associated with bacterial infection but does not distinguish between bacterial etiologies and has imperfect specificity distinguishing bacterial from viral pneumonia [2]. We assessed effects of combining pneumococcal density with CRP on sensitivity and specificity for distinguishing pneumococcal pneumonia from other pneumonia etiologies in the PERCH study.

METHODS

- PERCH is a 7 country case-control study of WHO-defined severe and very severe pneumonia in children 1-59 months of age.
- **Confirmed bacterial pneumonia:** bacteria detected by blood culture or by lung aspirate or pleural fluid culture or PCR, including confirmed pneumococcal (Spn) and other confirmed bacterial pneumonia cases (non-Spn).
- **RSV:** respiratory syncytial virus detected by PCR in NP/OP or induced sputum, excluding all confirmed bacterial cases; represents likely viral pneumonia
- **High-density Spn**: Spn PCR density in NP/OP > 6.6 log₁₀ copies/mL (> 4.4 if case received prior antibiotics) or whole blood > $2.2 \log_{10}$ copies/mL (thresholds derived comparing Spn-confirmed cases to PERCH community controls).
- We compared the percent with both elevated CRP and high density Spn in the different case groups.
- An **Optimal linear combination** of density and CRP was obtained using ROC analysis to derive a score that maximizes the Youden Index [3]; Spn-confirmed cases were compared to cases with other confirmed bacterial or RSV (i.e., combined).
- Sensitivity and specificity were calculated for the different methods of combining CRP with density; cases with other confirmed bacterial or RSV were combined for this analysis.

RESULTS

- The percent with both NP/OP high-density Spn and CRP \geq 40 mg/L was higher for Spnconfirmed cases (64%) than for cases with other confirmed bacterial (33%) or RSV (7%); among cases with prior antibiotics, the proportion was higher for RSV (19%) (Figures 1 and 3).
- The 'false positivity' of whole blood high-density Spn and CRP \geq 40 mg/L was lower (other confirmed bacterial cases=3%; RSV <1%) and sensitivity was also lower (50%) (Figures 1 and 3).
- CRP improved specificity over NP/OP high-density alone by 17-37%, but at loss to sensitivity of 12-25%; the addition of CRP to whole blood had only minor improvements to an already highly specific measure (from 97% to 99%) and with minor losses in sensitivity (from 58% to 52%) (Figure 3).

FIGURE 1. NP/OP pneumococcal PCR density and CRP distribution among different case groups by antibiotic use






FIGURE 2. Optimal linear combination of CRP with NP/OP and whole blood pneumococcal PCR density in distinguishing Spn-confirmed pneumonia cases from other confirmed bacterial and RSV cases



- The method of an optimal linear combination of CRP with density best distinguished case groups, generally by increasing sensitivity while maintaining fairly high specificity (Figures 2 and 3).
- The highest specificity measured was for high density Spn in NP/OP and whole blood (99%), with or without CRP.
- The highest sensitivity (87%) while still maintaining \geq 90% specificity was for the optimal linear combination of NP/OP density and whole blood and CRP which also maximized the combination of sensitivity and specificity (Figure 3).
- The linear combinations of CRP with density had higher specificity for RSV cases than for non-Spn confirmed bacterial cases (Figure 2).

Figure 3. Sensitivity and specificity of various definitions for Spn-confirmed cases using other confirmed bacterial cases and RSV+ cases as a single control group

			Specific	ity	Sensitivity								
-					NP/OP	Density + CRP among Cases without High density Spn alone* + CRP ≥ 40 mg/L + CRP ≥ 100 mg/L Optimal linear combination	Prior Ab	<u>x</u>		_	-		
				or Abx									
-					<u></u> 701	P Density + CRP among Cases with Pri High density Spn alone* + CRP ≥ 40 mg/L + CRP ≥ 100 mg/L Optimal linear combination					Ξ		
		Whole Blood Density + CRP among All Cases											
						High density Spn alone* + CRP ≥ 40 mg/L + CRP ≥ 100 mg/L Optimal linear combination				•			
=				<u>NP/0</u>	DP Den:	sity + Whole Blood Density + CRP am High density Spn in NP/OP and WB alone + CRP ≥ 40 mg/L + CRP ≥ 100 mg/L		<u>Cases</u>		-			
		_		N	P/OP De	Optimal linear combination ensity or Whole Blood Density + CRP High density Spn in NP/OP or WB alone* $+ CRP \ge 40 \text{ mg/L}$	among	All Cases			_		
						+ CRP ≥ 100 mg/L							
100	80	60	40	20	0		0	20	40	60	80	100	
	lensity Spr		defined as	≥ 6.6/4.4 lo	g ₁₀ (cop	ies/ml) for children without/with prior an	tibiotics.	High densi	ity Spn in v	vhole bloc	d defined		



CONCLUSIONS

- The method that maximized joint sensitivity and specificity was the optimal linear combination of NP/OP density and whole blood and CRP (sensitivity=87%, specificity=93%).
- Having CRP ≥ 40 in addition to high density Spn in NP/OP markedly increased specificity over density alone, especially among cases pretreated with antibiotics which reduces density of Spn in the NP/OP (increase in specificity of 35%).
- Sensitivity and specificity of whole blood high density alone was similar to that of **CRP** \ge 40 plus NP/OP high density (difference of 6% in both sensitivity and specificity) among those not pretreated with antibiotics.
- Linear combination 'scores' of CRP and density rather than combining binary cut-offs generally improved sensitivity at little cost to specificity and may be a useful method in etiology analyses.
- One limitation is that co-infection of Spn pneumonia with other pathogens cannot be ruled out, so specificity may not be correct.
- The value of adding CRP will depend on the viral:bacterial case mix (higher with more viral pneumonias, as in the post-PCV and Post-Hib vaccine era), or when high specificity is desired (e.g., estimating vaccine efficacy).

References

- 1. Albrich WC, Madhi SA, Adrian PV, et al. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. Clin Infect Dis. 2012;54:601-9
- 2. Flood RG. The utility of serum C-reactive protein in differentiating bacterial from nonbacterial pneumonia in children: a meta-analysis of 1230 children. Pediatr Infect Dis J. 2008: 27(2): 95.9.
- 3. Yin J and Tian L. Optimal linear combinations of multiple diagnostic biomarkers based on Youden Index. Stat Med. 2014; 33(8): 1426-40.

Funding: PERCH was supported by grant 48968 from The Bill & Melinda Gates Foundation to the International Vaccine Access Center, Department of International Health, Johns Hopkins Bloomberg School of Public Health.



© International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health 2016 All Rights Reserved. Johns Hopkins University International Vaccine Access Center • 415 N Washington Street • Baltimore, MD 21231 www.jhsph.edu/ivac • twitter: @IVACtweets

